Cwm, LLC Biogen Inc. Transaction History

Cwm, LLC

$21.2 Billion
Q2 2024

A detailed history of Cwm, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Cwm, LLC holds 3,765 shares of BIIB stock, worth $736,546. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,765

Previous 3,703 1.67%

Holding current value

$736,546

Previous $798,000 9.4%

% of portfolio

0.0%

Previous 0.0%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 09, 2024	BUY	$190.52 - $236.72 $11,812 - $14,676	62 Added 1.67%	3,765 $873,000
Q1 2024 Apr 05, 2024	BUY	$212.02 - $267.71 $51,944 - $65,588	245 Added 7.09%	3,703 $798,000
Q4 2023 Feb 01, 2024	SELL	$222.59 - $267.94 $44,518 - $53,588	-200 Reduced 5.47%	3,458 $895,000
Q3 2023 Oct 11, 2023	SELL	$253.3 - $285.89 $115,504 - $130,365	-456 Reduced 11.08%	3,658 $940,000
Q2 2023 Aug 03, 2023	BUY	$275.25 - $318.06 $361,128 - $417,294	1,312 Added 46.82%	4,114 $1.17 Million
Q1 2023 Apr 28, 2023	BUY	$256.56 - $292.34 $275,545 - $313,973	1,074 Added 62.15%	2,802 $779,000
Q4 2022 Feb 01, 2023	BUY	$252.44 - $306.72 $58,818 - $71,465	233 Added 15.59%	1,728 $479,000
Q3 2022 Oct 27, 2022	BUY	$194.69 - $268.46 $48,283 - $66,578	248 Added 19.89%	1,495 $399,000
Q2 2022 Jul 28, 2022	BUY	$187.54 - $223.02 $21,192 - $25,201	113 Added 9.96%	1,247 $254,000
Q1 2022 Apr 21, 2022	BUY	$193.77 - $244.14 $29,065 - $36,621	150 Added 15.24%	1,134 $239,000
Q4 2021 Jan 31, 2022	BUY	$223.92 - $287.77 $36,722 - $47,194	164 Added 20.0%	984 $236,000
Q1 2021 Sep 15, 2021	BUY	$242.95 - $284.63 $27,696 - $32,447	114 Added 16.15%	820 $284,000
Q1 2021 Apr 27, 2021	SELL	$242.95 - $284.63 $27,696 - $32,447	-114 Reduced 13.9%	706 $198,000
Q4 2020 Sep 15, 2021	BUY	$236.26 - $355.63 $89,306 - $134,428	378 Added 85.52%	820 $284,000
Q4 2020 Jan 27, 2021	SELL	$236.26 - $355.63 $89,306 - $134,428	-378 Reduced 46.1%	442 $108,000
Q3 2020 Sep 15, 2021	BUY	$264.77 - $305.71 $28,595 - $33,016	108 Added 15.17%	820 $284,000
Q3 2020 Oct 19, 2020	SELL	$264.77 - $305.71 $28,595 - $33,016	-108 Reduced 13.17%	712 $202,000
Q2 2020 Sep 15, 2021	BUY	$258.66 - $342.55 $36,471 - $48,299	141 Added 20.77%	820 $284,000
Q2 2020 Jul 22, 2020	SELL	$258.66 - $342.55 $36,471 - $48,299	-141 Reduced 17.2%	679 $182,000
Q1 2020 Sep 15, 2021	BUY	$268.85 - $341.04 $37,639 - $47,745	140 Added 20.59%	820 $284,000
Q1 2020 Apr 28, 2020	SELL	$268.85 - $341.04 $37,639 - $47,745	-140 Reduced 17.07%	680 $215,000
Q4 2019 Sep 14, 2021	BUY	$220.06 - $304.07 $37,410 - $51,691	170 Added 26.15%	820 $284,000
Q4 2019 Jan 27, 2020	SELL	$220.06 - $304.07 $37,410 - $51,691	-170 Reduced 20.73%	650 $193,000
Q3 2019 Sep 14, 2021	BUY	$217.44 - $243.88 $57,186 - $64,140	263 Added 47.22%	820 $284,000
Q3 2019 Oct 22, 2019	SELL	$217.44 - $243.88 $57,186 - $64,140	-263 Reduced 32.07%	557 $130,000
Q2 2019 Sep 14, 2021	SELL	$219.29 - $241.72 $657 - $725	-3 Reduced 0.36%	820 $284,000
Q2 2019 Jul 31, 2019	BUY	$219.29 - $241.72 $657 - $725	3 Added 0.37%	823 $192,000
Q1 2019 Sep 02, 2021	BUY	$216.71 - $338.96 $86,684 - $135,584	400 Added 95.24%	820 $0
Q1 2019 Apr 22, 2019	BUY	$216.71 - $338.96 $31,206 - $48,810	144 Added 52.17%	420 $99,000
Q4 2018 Jan 25, 2019	BUY	$278.5 - $352.75 $40,661 - $51,501	146 Added 112.31%	276 $83,000
Q3 2018 Oct 29, 2018	BUY	$293.51 - $383.83 $5,576 - $7,292	19 Added 17.12%	130 $46,000
Q2 2018 Jul 31, 2018	SELL	$257.52 - $306.91 $772 - $920	-3 Reduced 2.63%	111 $32,000
Q1 2018 Apr 26, 2018	BUY	$260.13 - $367.91 $11,445 - $16,188	44 Added 62.86%	114 $31,000
Q3 2017 Oct 16, 2017	BUY	$281.15 - $329.69 $19,680 - $23,078	70	70 $22,000

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $28.2B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account